Tumor Location as a Prognostic Factor in T1 Colorectal Cancer

Katsuro Ichimasa¹, Shin-ei Kudo¹, Yuta Kouyama¹, Kenichi Mochizuki¹, Yuki Takashina¹, Masashi Misawa¹, Yuichi Mori¹², Takemasa Hayashi¹, Kunihiko Wakamura¹ and Hideyuki Miyachi¹

¹) Digestive Disease Center, Showa University Northern Yokohama Hospital, Yokohama, Japan
²) Clinical Effectiveness Research Group, Institute of Health and Society, University of Oslo, Oslo, Norway

Abstract
The incidence of T1 colorectal cancer is expected to increase because of the prevalence of colorectal cancer screening and the progress of endoscopic treatment such as endoscopic submucosal dissection or endoscopic full-thickness resection. Currently, the requirement for additional surgery after endoscopic resection of T1 colorectal cancer is determined according to several treatment guidelines (in USA, Europe, and Japan) referring to the following pathological findings: lymphovascular invasion, tumor differentiation, depth of invasion, and tumor budding, all of which are reported to be risk factors for lymph node metastasis. In addition to these factors, in this review, we investigate whether tumor location, which is an objective factor, has an impact on the presence of lymph node metastasis and recurrence. From recent studies, left-sided location, especially the sigmoid colon in addition to rectum, could be a risk factor for lymph node metastasis and cancer recurrence. The treatment of T1 colorectal cancer should be managed considering these findings.

Keywords
tumor location, T1 colorectal cancer, lymph node metastasis, recurrence, risk factor, treatment strategy

Introduction
Colorectal cancer (CRC) is one of the most common types of cancer worldwide[1]. The number of treated cases of early CRC is expected to increase with increased CRC screening and the application of endoscopic treatment such as endoscopic submucosal dissection and endoscopic full-thickness resection. T1 CRC is defined as carcinoma that is confined to the submucosal layer and does not invade the muscularis propria. Because simultaneous lymph node metastasis (LNM) occurs in approximately 10% of T1 CRC cases, we should determine whether additional surgical resection is necessary after endoscopic resection of T1 CRC according to the risk of LNM based on the pathological findings[2-9]. Several guidelines state the risk factors for LNM, which include the depth of submucosal invasion, lymphovascular invasion, tumor differentiation, and tumor budding[10-18]. However, tumor location is not cited as a prognostic risk factor despite the fact that CRC progression is expected to vary according to tumor location due to anatomical differences. Tumor location differs from other histopathological factors and is an objective factor with an impact on treatment selection and management. Focusing particularly on recent studies, this review aimed to investigate whether tumor location has an impact on the rate of LNM and recurrence in T1 CRC. It further considers whether the treatment and follow-up strategy for T1 CRC should be selected according to tumor location.

Category of Tumor Location
Tumor location in CRC is divided into the following two
Table 1. Comparison of LNM in T1 CRC between the Colon and Rectum.

| Author (year)       | Location       | Type of study        | Patients, n | LNM %, n | OR (95% CI) | P value |
|---------------------|----------------|----------------------|-------------|----------|-------------|---------|
| Kang et al. (2020)  | Korea          | Single center        | 221         | 10.9% 14/129 | 1.6 (0.72–3.53) | 0.239*  |
| Ronnow et al. (2020)| Sweden         | SCRCR database       | 1439        | 10.0% 105/1054 | 0.934 (0.620–1.408) | 0.745** |
| Oh et al. (2019)    | Korea          | Single center        | 833         | 13.1% 70/536 | 0.67 (0.42–1.06) | 0.089*  |
| Barel et al. (2019) | France         | FDCR database        | 234         | 6.8% 12/177  | N/A         | 0.2616* |
| Miyachi et al. (2016)| Japan        | Single center        | 653         | 8.4% 39/463 | 1.35 (0.73–2.43) | 0.299*  |
| Macias et al. (2015)| Germany       | Single center        | 97          | 13.4% 9/67  | N/A         | 0.675*  |
| Bosch et al. (2013) | Netherlands    | Meta-analysis        | 2722 (10 studies [39, 53–61]) | 9.9% 169/1699 | 1.4 (1.1–1.7)  | <0.001* |

LNM, lymph node metastasis; CRC, colorectal cancer; OR, odds ratio; CI, confidence interval; SCRCR, Swedish Colorectal Cancer Registry; FDCR, Finistère Digestive Cancers Registry; N/A, not applicable; *univariate analysis; **multivariate analysis

1. Colon vs rectum

Most studies report that rectal cancer patients have a statistically equal or higher rate of LNM compared with T1 CRC patients (Table 1)[6,20-25]. Several studies presented no significant difference in the rate of LNM between colon and rectal T1 cancer patients (colon vs rectum: Oh et al., 13.1% vs 9.1%, p = 0.089; Barel et al., 6.8% vs 12.3%, p = 0.2616; Miyachi et al., 8.4% vs 11.1%, p = 0.299; and Macias et al., 13.4% vs 16.7%, p = 0.675)[6,23-25]. Using the Swedish Colorectal Cancer Registry with 1439 patients with T1 CRC[22], Ronnow et al. demonstrated that rectal cancer patients (11.7%) showed no significant difference in terms of LNM rate compared with colon cancer patients (10.0%) in univariate (odds ratio [OR] = 1.196, 95% confidence interval [CI] 0.826-1.733, p = 0.343) and multivariate (OR = 0.934, 95% CI 0.620–1.408, p = 0.745) analyses. Although many of these studies showed a higher rate of LNM in rectal cancer patients, there was no significant difference, possibly because of the limited sample size. Bosch et al. performed a systematic review of 10 studies with 2722 patients[5]. In their study, rectal cancer patients demonstrated a significantly higher rate of LNM than those with colon cancer (colon: 9.9%, 169/1699; rectum: 13.8% 141/1023; OR = 1.4, 95% CI 1.1-1.7, p < 0.001).

2. Right-sided vs left-sided CRC

Several studies reported a higher rate of LNM in left-sided cancer patients than in right-sided cancer patients with T1 CRC (Table 2)[9,26-28]. Papers published in 2020-2021 compared the rate of LNM between right- and left-sided colon patients[26-28], and the conclusions were the same for all. Ouchi et al. investigated the rate of LNM in 458 T1 CRC patients and showed that those with right-sided colon cancer had a lower rate of LNM than patients with left-sided CRC (6/126 [4.8%] vs. 36/332 [10.8%], p = 0.04)[28]. The authors referred to genetic and anatomical characteristics as potential reasons for such differences. Mochizuki et al. also reported that left-sided T1 cancer patients showed significantly higher rates of LNM than those with right-sided cancer (left-sided 63/527 [12.0%] vs. right-sided 12/218 [5.5%], p < 0.05) in a retrospective single-center study investigating 745 T1 CRC patients[26]. They speculated that this difference was owing to the frequency of occurrence of lymphatic invasion, which was the most reliable predictor for LNM, was significantly higher in left-sided cancer patients than in those with right-sided cancer (left-sided 32.7% vs. right-sided 23.2%, p < 0.05), although the mechanism was un-
clear. In addition to these single-center studies, Kudo et al. performed a multicenter study at seven institutions in Japan to develop an artificial intelligence model predicting the presence of LNM in T1 CRC patients[9]. In their study of 3134 patients with T1 CRC, left-sided location was also an independent risk factor for LNM (OR = 1.44, 95% CI 1.08–1.92, p = 0.01). Guo et al. used the Surveillance, Epidemiology, and End Results (SEER) database information for 2004-2016 to investigate a much larger population with T1 CRC[27]. The SEER database is one of the largest publicly accessible databases globally, covering approximately 30% of all cancers and including 18 population-based cancer registries in the USA (http://seer.cancer.gov/about/overview.htm l). This study of 16,106 T1 CRC patients showed that left-sided cancer was an independent risk factor for LNM in univariate (OR = 1.72, 95% CI 1.56-1.89) and multivariate (OR = 1.59, 95% CI 1.43-1.76) analyses. Thus, Dang et al. investigated the tumor-stroma ratio, which is reported to be a strong independent prognostic factor in advanced stage CRC, with high stromal occupancy being associated with worse prognosis and survival[29]. In their study, the left-sided colon showed a statistically higher stroma ratio than the right-sided colon (34% vs. 20%, respectively), which may be associated with the difference in LNM between the right- and left-sided colon cancer patients. In addition, for advanced CRC, many differences have been reported between right- and left-sided cancer: in right-sided cancer patients, who are more often women, microsatellite instability, CIMP/BRAF mutation, MAPK signaling, serrated pathway, mutagenic CYP450 metabolites, and HNPPC were more prevalent; in left-sided cancer patients, who are more likely men, chromosomal instability, APC/KRAS/DCC/TP53 mutations, EGFR signaling, Wnt signaling, HER1, HER2 amplification, and FAP were reported[30-34]. From these studies, a consensus that left-sided T1 CRC patients show a higher rate of LNM than those with right-sided cancer was reached.

### 3. Cecum, ascending colon, transverse colon, descending colon, sigmoid colon, and rectum

The sigmoid colon and rectum present a higher rate of LNM than other locations in T1 CRC patients. Some studies showed a correlation between each location in the colorectum and the presence of LNM (Table 3)[26,35-38]. Miyachi et al. and Mochizuki et al. investigated tumor location and LNM in 745 patients who underwent surgical resection with lymph node dissection[26,35]. Of these, LNM was observed in 10.1% of the patients (75/745). Interestingly, the sigmoid colon and the rectum showed a higher rate of LNM (sig-
moid colon: 45/363 [12.4%] and rectum: 17/141 [12.1%]) than the other sites (cecum [C]: 5.3%, ascending colon [A]: 3.8%, transverse colon [T]: 7.9%, and descending colon [D]: 4.3%), which was notably higher in the sigmoid colon in women (26/136 [19.1%]). Furthermore, using the SEER database, Xu et al. reported that the sigmoid colon showed the highest OR (1.26, 95% CI 1.05-1.53, p = 0.014) for LNM in adjusted logistic regression analysis compared with other colon sites excluding the rectum (C: ref, A: OR = 0.77, 95% CI 0.62-0.96; HF: OR = 0.91, 95% CI 0.63-1.29; T: OR = 0.81, 95% CI 0.5-1.10; SF: OR = 0.63, 95% CI 0.33-1.11; D: OR = 0.92, 95% CI 0.64-1.28)[36]. A study by Yim et al. showed a different pattern of LNM, in which the cecum presented a high LNM rate (20%, 1/5), but the number of samples might have been insufficient. What these studies have in common is that many T1 CRCs are found in the sigmoid colon and rectum. Furthermore, from these studies, sigmoid colon could present the highest rate of LNM among other colon sites except the rectum in T1 CRC. A high rate of LNM in sigmoid colon is responsible for the high rate LNM in the left-sided colon and may be one of the factors for which there are no statistically significant differences in LNM between the colon and rectum.

4. Lower rectum vs upper rectum

The distance of primary tumor from the anal verge is of critical value, not only to determine the risk of LNM but also to decide whether to perform surgical resection that directly affects patients’ quality of life. Therefore, we also reviewed the differences in LNM between the lower rectum and other sites in the rectum (including the upper and middle rectum) (Table 4)[39-42]. Nascimbeni et al. reported that 10 of 29 patients (34%) had LNM in the lower rectum and 9 of 90 (10%) had LNM in other sites in the rectum[39]. In a multivariate analysis that included colon cancer patients (n = 353), the lower rectum showed a significantly higher rate of LNM compared with other sites in the colorectum (OR = 6.0, 95% CI 2.2-14.2; p < 0.001). In three of four studies, the lower rectum showed a higher rate of LNM compared with other sites in the rectum, even though they were limited by their small sample sizes[39-41].

Recurrence

There is a consensus from most studies that rectal T1 cancer presents a higher recurrence rate than colon T1 cancer, regardless of the treatment strategy[43-47]. In a single-center study of 930 T1 CRC patients, Kouyama et al. reported that rectal location was a significant risk factor for recurrence in the total population, including endoscopic resection alone and surgical resection. Rectal cancer accounted for 6 out of 10 cases with recurrence (rectum; 3.6%; colon; 0.5%) and the rectum showed OR = 6.58 (95%CI, 1.83-23.63) for recurrence compared with the colon in Cox regression analysis. Yoda et al. and Yoshii et al. reported a similar tendency (rectum, 9.9% (10/101) and 14.5% (8/55); colon, 1.5% (5/327) and 2.3% (9/323), respectively)[44,45]. In 2020, a meta-analysis of 11 studies by Dang et al. revealed that the rectal cancer also indicated a higher recurrence rate than the colon cancer (colon, 0.8%, 95%CI 0.2-2.8; rectum, 5.7%, 95% CI 2.0-15.2)[47]. Finally, Ikematsu et al. investigated the recurrence rate between the colon and rectum dividing 758 T1 CRC patients into two groups according to the LNM risk in a multicenter study[46]. In the high-risk group for LNM, which had lymphovascular invasion, tumor differentiation, depth of invasion or tumor budding, the recurrence difference (OR, 6.73 [95%CI 1.04-43.43], p = 0.045) was stronger compared with the difference in the low-risk group. The possibility that this difference could result from the under-treatment of high-risk rectal T1 cancer cannot be ignored, although there was no significant difference in the rate of endoscopic resection alone for high-risk T1 cancer patients (colon 12.0% vs. rectum 17.3%, p = 0.06) in addition to the anatomical or biological differences between the colon and rectum. Similar trends were noted in another study (colon 32% vs rectum 44%)[45]. In particular, patients’ refusal of additional surgery after endoscopic resection was observed more frequently in the lower rectum than in other sites in the colorectum, leading to worse prognosis (5-year RFS of 77.7% in the lower rectum, 96.5% in other

Table 4. Comparison of LNM between Lower Rectum and Upper Rectum in T1 Cancer.

| Author (year)   | Location | Type of study | Patients, n | LNM %, n | OR (95% CI) | P value |
|-----------------|----------|---------------|-------------|----------|-------------|---------|
| Aytac et al. (2016) | US       | Single center | 68          | 11.1% 2/18 | 18% 9/50     | N/A N/A |
| Nakadoi et al. (2014) | Japan    | Single center | 78          | 18.8% 6/32 | 10.9% 5/46   | N/A N/A |
| Nascimbeni et al. (2002) | US       | Single center | 119         | 34% 10/34 | 10% 9/90     | N/A 0.007* |
| Kikuchi et al. (1995) | Japan    | Single center | 84          | 17.3% 9/52 | 3.1% 1/32    | N/A N/A |

LNM, lymph node metastasis; OR, odds ratio; CI, confidence interval; N/A, not applicable; *univariate analysis

dx.doi.org/10.23922/jarc.2021-029
sites)]\(^{46,48}\). Importantly, these studies indicated that surgical resection with lymph node dissection in patients with rectal T1 cancer with high-risk factors for LNM is highly recommended to decrease the recurrence rate. QOL-preserving treatments such as adjuvant chemoradiotherapy after endoscopic resection could be required as an alternative option to replace additional surgical resection for such lesions to reduce the risk of recurrence.

Ouchi et al. investigated the differences in recurrence between right- and left-sided cancer in 458 patients with T1 CRC\(^{[28]}\). Left-sided cancer showed a higher recurrence rate than right-sided cancer (0/126 [0\%] vs 7/332 [2.1\%], \(p = 0.10\)), even though there was no significant difference. Similarly, Guo et al. reported that left-sided cancer presented OR = 1.86 (95\% CI 1.36-2.58, \(p < 0.001\)) in univariate analysis and OR = 1.43 (95\% CI 1.00-2.07, \(p = 0.054\)) for distant metastasis compared with right-sided cancer. As well as LNM, the number of recurrences in the sigmoid colon in addition to the rectum was high compared with other colon sites (sigmoid, 3/10 vs other colon sites, 1/10\(^{[43]}\); sigmoid 4/15 vs other colon 1/15\(^{[45]}\)). This might be because left-sided CRC, especially in the sigmoid colon and the rectum, was reported to show higher rates of LNM that were correlated with recurrence compared with right-sided T1 cancer. This was despite the fact that although the number of dissected lymph nodes were usually fewer in left-sided CRCs than in right-sided CRCs, with the lowest from rectal cancers, leading to an underestimation of LNM. International guidelines restrict their recommendations to a minimum number of 10 to 12 lymph nodes in CRC to represent both a prognostic marker and an indicator of the quality of surgical resection\(^{[14,16,49]}\). Regarding T1 CRC, Bakes et al. reported that a lymph node yield of <10 was associated with an increased risk of recurrence after surgical resection\(^{[50]}\). In addition, the number of lymph nodes retrieved in left-sided disease including the rectum was less than in right-sided\(^{[50,51]}\). This difference may be because right-sided CRC resection specimens were longer than left-sided CRCs, or there was variable lymphatic anatomy between them\(^{[52]}\). From these studies, the number of retrieved lymph nodes was similar to advanced CRC could be necessary, even for T1 CRC, to reduce the risk of recurrence.

**Conclusion**

This review investigated the differences in LNM and recurrence in T1 CRC patients according to tumor location. Many T1 CRCs are located in the sigmoid colon and rectum, and the frequency of both LNM and recurrence was higher in left-sided T1 cancer, especially in the sigmoid colon and rectum, than in right-sided T1 cancer in most studies. Although stronger evidence is required regarding any additional treatment or surveillance by tumor location to reflect on the treatment guidelines, we must consider these backgrounds when treating and managing T1 CRC.

**Acknowledgements**

We thank H. Nikki March, PhD, from Edanz Group (https://en-author-services.edanz.com/ac) for editing a draft of this manuscript.

**Conflicts of Interest**

There are no conflicts of interest.

**Author Contributions**

Conception and design: K.I.; Drafting the article: K.I.; Literature search: K.I., Y.K., K.M., Y.T.; Critical revision: S.K., Y.K., K.M., Y.T., M.M., Y.M., T.H., K.W., H.M.; Study supervision: S.K., H.M.

**References**

1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021 May; 71(3): 209-49.
2. Ichimasa K, Kudo SE, Miyachi H, et al. Risk stratification of T1 colorectal cancer metastasis to lymph nodes: current status and perspective. Gut Liver. 2020 Dec, online ahead of print.
3. Ichimasa K, Kudo SE, Mori Y, et al. Artificial intelligence may help in predicting the need for additional surgery after endoscopic resection of T1 colorectal cancer. Endoscopy. 2018 Mar; 50(03): 230-40.
4. Yasue C, Chino A, Takamatsu M, et al. Pathological risk factors and predictive endoscopic factors for lymph node metastasis of T1 colorectal cancer: a single-center study of 846 lesions. J Gastroenterol. 2019 Aug; 54(8): 708-17.
5. Bosch SL, Teerenstra S, de Wilt JH, et al. Predicting lymph node metastasis in pT1 colorectal cancer: a systematic review of risk factors providing rationale for therapy decisions. Endoscopy. 2013 Oct; 45(10): 827-34.
6. Miyachi H, Kudo SE, Ichimasa K, et al. Management of T1 colorectal cancers after endoscopic treatment based on the risk stratification of lymph node metastasis. J Gastroenterol Hepatol. 2016 Jun; 31(6): 1126-32.
7. Backes Y, Elias SG, Groen JN, et al. Histologic factors associated with need for surgery in patients with pedunculated T1 colorectal carcinomas. Gastroenterology. 2018 May; 154(6): 1647-59.
8. Nishimura T, Oka S, Tanaka S, et al. Clinical significance of immunohistochemical lymphovascular evaluation to determine additional surgery after endoscopic submucosal dissection for colorectal T1 carcinoma. Int J Colorectal Dis. 2021 May; 36(5): 949-58.
9. Kudo SE, Ichimasa K, Villard B, et al. Artificial intelligence system to determine risk of T1 colorectal cancer metastasis to lymph node. Gastroenterology. 2021 Mar; 160(4): 1075-84.
10. Hashiguchi Y, Muro K, Saito Y, et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer. Int J Clin Oncol. 2020 Jan; 25(1): 1-42.
11. Park CH, Yang DH, Kim JW, et al. Clinical practice guideline for endoscopic resection of early gastrointestinal cancer. Clin Endosc. 2020 Mar; 53(2): 142-66.
12. Kaltenbach T, Anderson JC, Burke CA, et al. Endoscopic removal of colorectal lesions-recommendations by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology. 2020 Mar; 158(4): 1095-129.
13. Benson AB, Venook AP, Al-Hawary MM, et al. Rectal cancer, version 2.2018, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2018 Jul; 16(7): 874-901.
14. Benson AB, 3rd, Venook AP, Cederquist L, et al. Colon cancer, version 1.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 2017 Mar; 15(3): 370-98.
15. Glyn-Jones R, Wyrwicz L, Tirtel E, et al. Rectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018 Jul; 29 Suppl 4: iv263.
16. Labianca R, Nordlinger B, Beretta GD, et al. Early colon cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013 Oct; 24 Suppl 6: vi64-72.
17. Pimentel-Nunes P, Dinis-Ribeiro M, Ponchon T, et al. Endoscopic submucosal dissection: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy. 2015 Sep; 47(9): 829-54.
18. Diagnosis, Treatment Guidelines For Colorectal Cancer Working Group C. Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for colorectal cancer 2018 (English version). Chin J Cancer Res = Chung-kuo yen cheng yen chiu. 2019 Feb; 31(1): 117-34.
19. Japanese Society for Cancer of the C, Rectum. Japanese classification of colorectal, appendiceal, and anal carcinoma: the 3d English Edition [Secondary Publication]. J Anus, Rectum and Colon. 2019 Oct; 3(4): 175-95.
20. Wang H, Wei XZ, Fu CG, et al. Patterns of lymph node metastasis are different in colon and rectal carcinomas. World J Gastroenterol. 2010 Nov; 16(42): 5375-9.
21. Kang J, Choi YJ, Kim IK, et al. Lasso-based machine learning algorithm for prediction of lymph node metastasis in T1 colorectal cancer. Cancer Res Treat. 2020 Jul; 53(3): 773.
22. Rönnof CF, Arthursson V, Toth E, et al. Lymphovascular infiltration, not depth of invasion, is the critical risk factor of metastases in early colorectal cancer: retrospective population-based cohort study on prospectively collected data, including validation. Ann Surg. 2020 Mar, online ahead of print.
23. Oh JR, Park B, Lee S, et al. Nomogram development and external validation for predicting the risk of lymph node metastasis in T1 colorectal cancer. Cancer Res Treat. 2019 Oct; 51(4): 1275-84.
24. Barel F, Cariou M, Saliou P, et al. Histopathological factors help to predict lymph node metastases more efficiently than extra-nodal recurrences in submucosa invading pT1 colorectal cancer. Sci Rep. 2019 Jun; 9(1): 8342.
25. Macias-Garcia F, Celeiro-Muñoz C, Lesquereux-Martinez L, et al. A clinical model for predicting lymph node metastasis in submucosal invasive (T1) colorectal cancer. Int J Colorectal Dis. 2015 Jun; 30(6): 761-8.
26. Mochizuki K, Kudo SE, Ichimasa K, et al. Left-sided location is a risk factor for lymph node metastasis of T1 colorectal cancer: a single-center retrospective study. Int J Colorectal Dis. 2020 Oct; 35(10): 1911-9.
27. Guo K, Feng Y, Yuan L, et al. Risk factors and predictors of lymph nodes metastasis and distant metastasis in newly diagnosed T1 colorectal cancer. Cancer Med. 2020 Jul; 9(14): 5095-113.
28. Ouchi A, Toriyama K, Kinoshita T, et al. Variations in clinical features and oncologic behaviors of T1 colorectal cancer according to tumor location. Int J Clin Oncol. 2020 Jun; 25(6): 1130-6.
29. Dang H, van Pelt GW, Haasnoot KJ, et al. Tumour-stroma ratio has poor prognostic value in non-pedunculated T1 colorectal cancer: a multi-centre case-cohort study. U Eur Gastroenterol J. 2021 May; 9(4): 478-85.
30. He WZ, Liao FX, Jiang C, et al. Primary tumor location as a predictive factor for first-line bevacizumab effectiveness in metastatic colorectal cancer patients. J Cancer. 2017 Feb; 8(3): 388-94.
31. Weiss JM, Pfau PR, O’Connor ES, et al. Mortality by stage for right- versus left-sided colon cancer: analysis of surveillance, epidemiology, and end results—medicare data. J Clin Oncol. 2011 Nov; 29(33): 4401-9.
32. Salem ME, Weinberg BA, Xiu J, et al. Comparative molecular analyses of left-sided colon, right-sided colon, and rectal cancers. Oncotarget. 2017 Sep; 8(49): 86356-68.
33. Petrelli F, Tomasello G, Borgonovo K, et al. Prognostic survival associated with left-sided vs right-sided colon cancer: a systematic review and meta-analysis. JAMA Oncol. 2017 Feb; 3(2): 211-9.
34. Meguid RA, Slidell MB, Wolfgang CL, et al. Is there a difference in survival between right- versus left-sided colon cancers? Ann Surg Oncol. 2008 Sep; 15(9): 2388-94.
35. Miyachi H, Kudo S, Mochizuki K, et al. Tumor location and patient sex are novel risk factors of lymph node metastasis in T1 colorectal cancer. J Gastroenterol Hepatol. 2020 Dec; 35(12): 2292.
36. Xu X, Zhang C, Ni X, et al. Population-based analysis on predictors for lymph node metastasis in T1 colon cancer. Surg Endosc. 2020 Sep; 34(9): 4030-40.
37. Yim K, Won DD, Lee IK, et al. Novel predictors for lymph node metastasis in submucosal invasive colorectal carcinoma. World J Gastroenterol. 2017 Aug; 23(32): 5936-44.
38. Toh EW, Brown P, Morris E, et al. Area of submucosal invasion and width of invasion predicts lymph node metastasis in pT1 colorectal cancers. Dis Colon Rectum. 2015 Apr; 58(4): 393-400.
39. Nascimbeni R, Burgart LJ, Nivatvongs S, et al. Risk of lymph node metastasis in T1 carcinoma of the colon and rectum. Dis Col- lon Rectum. 2002 Feb; 45(2): 200-6.
40. Nakadoi K, Oka S, Tanaka S, et al. Condition of muscularis mucosae is a risk factor for lymph node metastasis in T1 colorectal carcinoma. Surg Endosc. 2014 Apr; 28(4): 1269-76.
41. Kikuchi R, Takano M, Takagi K, et al. Management of early invasive colorectal cancer. Risk of recurrence and clinical guidelines. Dis Colon Rectum. 1995 Dec; 38(12): 1286-95.
42. Aytaç E, Gorgun E, Costedio MM, et al. Impact of tumor location on lymph node metastasis in T1 colorectal cancer. Langenbecks Arch Surg. 2016 Aug; 401(5): 627-32.
43. Koyama Y, Kudo SE, Miyachi H, et al. Risk factors of recurrence in T1 colorectal cancers treated by endoscopic resection alone or surgical resection with lymph node dissection. Int J Colorectal Dis. 2018 Aug; 33(8): 1029-38.
44. Yoshii S, Nojima M, Nosho K, et al. Factors associated with risk for colorectal cancer recurrence after endoscopic resection of T1 tumors. Clin Gastroenterol Hepatol. 2014 Feb; 12(2): 292-302.
45. Yoda Y, Ikematsu H, Matsuda T, et al. A large-scale multicenter study of long-term outcomes after endoscopic resection for submucosal invasive colorectal cancer. Endoscopy. 2013 Sep; 45(9): 718-24.
46. Ikematsu H, Yoda Y, Matsuda T, et al. Long-term outcomes after resection for submucosal invasive colorectal cancers. Gastroen-
terology. 2013 Mar;144(3): 551-9; quiz e514.

47. Dang H, Dekkers N, le Cessie S, et al. Risk and time pattern of recurrences after local endoscopic resection of T1 colorectal cancer: a meta-analysis. Clin Gastroenterol Hepatol. 2020 Dec, online ahead of print.

48. Kitaguchi D, Sasaki T, Nishizawa Y, et al. Long-term outcomes and lymph node metastasis in patients receiving radical surgery for pathological T1 lower rectal cancer. World J Surg. 2019 Feb;43 (2): 649-56.

49. Parsons HM, Begun JW, Kuntz KM, et al. Lymph node evaluation for colon cancer in an era of quality guidelines: who improves? J Oncol Pract. 2013 Jul;9(4): e164-71.

50. Backes Y, Elias SG, Bhoelan BS, et al. The prognostic value of lymph node yield in the earliest stage of colorectal cancer: a multicenter cohort study. BMC Med. 2017 Dec;15(1): 129.

51. Son SM, Woo CG, Lee OJ, et al. Factors affecting retrieval of 12 or more lymph nodes in pT1 colorectal cancers. J Int Med Res. 2019 Oct;47(10): 4827-40.

52. Chou JF, Row D, Gonen M, et al. Clinical and pathologic factors that predict lymph node yield from surgical specimens in colorectal cancer: a population-based study. Cancer. 2010 Jun;116(11): 2560-70.

53. Kitamura K, Taniguchi H, Yamaguchi T, et al. Clinical outcome of surgical treatment for invasive early colorectal cancer in Japan. Hepato-gastroenterology. 1997 Jan;44(13): 108-15.

54. Yamamoto S, Watanabe M, Hasegawa H, et al. The risk of lymph node metastasis in T1 colorectal carcinoma. Hepato-gastroenterology. 2004 Jul;51(58): 998-1000.

55. Ishii M, Ota M, Saito S, et al. Lymphatic vessel invasion detected by monoclonal antibody D2-40 as a predictor of lymph node metastasis in T1 colorectal cancer. Int J Colorectal Dis. 2009 Sep;24(9): 1069-74.

56. Ishikawa Y, Akishima-Fukasawa Y, Ito K, et al. Histopathologic determinants of regional lymph node metastasis in early colorectal cancer. Cancer. 2008 Feb;112(4): 924-33.

57. Kitajima K, Fujimori T, Fujii S, et al. Correlations between lymph node metastasis and depth of submucosal invasion in submucosal invasive colorectal carcinoma: a Japanese collaborative study. J Gastroenterol. 2004 Jun;39(6): 534-43.

58. Masaki T, Matsuoka H, Sugiyama M, et al. Actual number of tumor budding as a new tool for the individualization of treatment of T1 colorectal carcinomas. J Gastroenterol Hepatol. 2006 Jul;21(7): 1115-21.

59. Rasheed S, Bowley DM, Aziz O, et al. Can depth of tumour invasion predict lymph node positivity in patients undergoing resection for early rectal cancer? A comparative study between T1 and T2 cancers. Colorectal Dis. 2008 Mar;10(3): 231-8.

60. Suzuki T, Sadahiro S, Mukoyama S, et al. Risk of lymph node and distant metastases in patients with early invasive colorectal cancer classified as Haggitt’s Level 4 invasion: image analysis of submucosal layer invasion. Dis Colon Rectum. 2003 Feb;46(2): 203-8.

61. Wang HS, Liang W-Y, Lin T-C, et al. Curative resection of T1 colorectal carcinoma: risk of lymph node metastasis and long-term prognosis. Dis Colon Rectum. 2005 Jun;48(6): 1182-92.